AJOVY is indicated for the preventive treatment of migraine in adults.

You can also browse the topics below to find what you are looking for.

A frustrated patient sits atop a neon NOW sign looking to the HCP for help with her migraine. Now is the time for AJOVY.

THE #1 PREVENTIVE ANTI-CGRP in new prescriptions among the top headache centers combined1*

Check your local coverage Are drug-drug interactions likely with AJOVY? Does AJOVY bind to the ligand or receptor?
 

The long-acting anti-CGRP injection with lasting protection against migraine2†

​

*Based on third-party USA data from IQVIA, top headache centers are defined as the top 50 treatment centers with the highest new preventive anti-CGRP prescription volume, that have 2 or more prescribers, 50 or more new prescriptions for anti-CGRPs, and 170 or more total prescriptions for anti-CGRPs (December 2023 – February 2024).

†“Long-acting” and “lasting protection” defined as reduction in monthly average migraine or headache days (chronic migraine: 4.6 and 4.3 fewer headache days of at least moderate severity with monthly and quarterly dosing, respectively, vs 2.5 with placebo; episodic migraine: 3.7 and 3.4 fewer migraine days with monthly and quarterly dosing, respectively, vs 2.2 with placebo) measured over a 12-week period following a monthly 225 mg SC dose or quarterly 675 mg (225 mg x 3) SC dose.2

CGRP: calcitonin gene-related peptide; SC: subcutaneous.

References: 1. Data on file. Parsippany, NJ: Teva Pharmaceuticals USA, Inc. 2. AJOVY® (fremanezumab-vfrm) injection Current Prescribing Information. North Wales, PA: Teva Pharmaceuticals USA, Inc.